Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_4
1
33%
Ph phase_1
2
67%

Phase Distribution

2

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (66.7%)
Phase 41 (33.3%)

Trials by Status

completed3100%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_1

Abuse Potential of Sativex

NCT01323569
completedphase_4

The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain

NCT01598207
completedphase_1

Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting Conditions

NCT01380457

Clinical Trials (3)

Showing 3 of 3 trials
NCT01323569Phase 1

Abuse Potential of Sativex

Completed
NCT01598207Phase 4

The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain

Completed
NCT01380457Phase 1

Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting Conditions

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3